Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany

References

• Koch-HenriksenNSorensenPSThe changing demographic pattern of multiple sclerosis epidemiologyLancet Neurol20109552053220398859
   PubMed Web of Science ®Google Scholar
• FlacheneckerPStukeKEliasWMultiple sclerosis registry in Germany: results of the extension phase 2005/2006Dtsch Arztebl Int2008105711311919633761
   PubMed Web of Science ®Google Scholar
• KobeltGBergJLindgrenPCosts and quality of life of multiple sclerosis in GermanyEur J Health Econ20067Suppl 2S34S4417310337
   PubMedGoogle Scholar
• ReeseJPJohnAWienemannGEconomic burden in a German cohort of patients with multiple sclerosisEur Neurol201166631132122086151
   PubMed Web of Science ®Google Scholar
• FrischerJMBramowSDal-BiancoAThe relation between inflammation and neurodegeneration in multiple sclerosis brainsBrain2009132Pt 51175118919339255
   PubMed Web of Science ®Google Scholar
• KapposLMoeriDRadueEWPredictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis GroupLancet1999353915796496910459905
   PubMed Web of Science ®Google Scholar
• MillerDHGrossmanRIReingoldSCMcFarlandHFThe role of magnetic resonance techniques in understanding and managing multiple sclerosisBrain1998121Pt 13249549485
   PubMed Web of Science ®Google Scholar
• BjartmarCKiddGMorkSRudickRTrappBDNeurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patientsAnn Neurol200048689390111117546
   PubMed Web of Science ®Google Scholar
• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• NickersonMCofieldSSTyryTSalterARCutterGRMarrieRAImpact of multiple sclerosis relapse: the NARCOMS participant perspectiveMult Scler Relat Disord20154323424026008940
   PubMed Web of Science ®Google Scholar
• Weinstock-GuttmanBGalettaSLGiovannoniGAdditional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MSJ Neurol2012259589890522008873
   PubMed Web of Science ®Google Scholar
• TyasDKerriganJRussellNNixonRThe distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity?Value Health200710538638917888103
   PubMed Web of Science ®Google Scholar
• BourdetteDNProchazkaAVMitchellWLicariPBurksJHealth care costs of veterans with multiple sclerosis: implications for the rehabilitation of MS. VA Multiple Sclerosis Rehabilitation Study GroupArch Phys Med Rehabil199374126318420515
   PubMed Web of Science ®Google Scholar
• NaciHFleurenceRBirtJDuhigAEconomic burden of multiple sclerosis: a systematic review of the literaturePharmacoeconomics201028536337920402540
   PubMed Web of Science ®Google Scholar
• WindtRGlaeskeGHoffmannFTreatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patientsInt J Clin Pharm20133561229123524104761
   PubMed Web of Science ®Google Scholar
• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• SpelmanTKalincikTZhangAComparative efficacy of switching to natalizumab in active multiple sclerosisAnn Clin Transl Neurol20152437338725909083
   PubMed Web of Science ®Google Scholar
• HutchinsonMKapposLCalabresiPAThe efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINELJ Neurol2009256340541519308305
   PubMed Web of Science ®Google Scholar
• Tysabri (natalizumab): Summary of Product CharacteristicsBerkshire, UKBiogen2006
   Google Scholar
• GKV-SpitzenverbandShaping Health Together in Europe: Position Paper by the National Association of Statutory Health Insurance Funds2014 Available from: https://www.gkv-spitzenverband.de/media/dokumente/presse/publikationen/P140184_GKV_PP_Europa_EN_bar-rierefrei.pdfAccessed June 29, 2015
   Google Scholar
• GKV-SpitzenverbandStatutory health insurance2015 Available from: https://www.gkv-spitzenverband.de/english/statutory_health_insurance/statutory_health_insurance.jspAccessed June 29, 2015
   Google Scholar
• PetersenGWittmannRArndtVGopffarthDEpidemiology of multiple sclerosis in Germany: regional differences and drug prescription in the claims data of the statutory health insuranceNervenarzt2014858990998 German25022894
   PubMed Web of Science ®Google Scholar
• AndersohnFWalkerJCharacteristics and external validity of the German Health Risk Institute (HRI) DatabasePharmacoepidemiol Drug Saf201625110610926530279
   PubMed Web of Science ®Google Scholar
• Statistisches BundesamtGerman population as of December 31, 2011 (based on 2011 census data): gender2015 Available from: https://www.destatis.de/EN/FactsFigures/SocietyState/Population/CurrentPopulation/Tables/Census_SexAndCitizenship.htmlAccessed July 2, 2015
   Google Scholar
• Statistisches BundesamtGerman population as of December 31, 2011 (based on 2011 census data): population by age group2015 Available from: https://www.destatis.de/EN/FactsFigures/SocietyState/Population/CurrentPopulation/Tables_/lrbev01.htmlAccessed July 2, 2015
   Google Scholar
• DeyoRACherkinDCCiolMAAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol19924566136191607900
   PubMed Web of Science ®Google Scholar
• CharlsonMEPompeiPAlesKLMacKenzieCRA new method of classifying prognostic comorbidity in longitudinal studies: development and validationJ Chronic Dis19874053733833558716
   PubMedGoogle Scholar
• DienerHCWeimarCDiagnostik und Therapie der Multiplen Sklerose. Leitlinien für Diagnostik und Therapie in der Neurologie [Diagnostics and therapy of multiple sclerosis. Guidelines for diagnostics and therapy in neurology]Stuttgart, GermanyThieme Verlag2012 German
   Google Scholar
• Statistisches BundesamtConsumer price index and inflation rate2013 Available from: https://www.destatis.de/EN/FactsFigures/NationalEconomyEnvironment/Prices/ConsumerPriceIndices/Basket-GoodsServicesWeightingPattern/CPIVideo.htmlAccessed June 29, 2015
   Google Scholar
• HoerASchiffhorstGZimmermannAMultiple sclerosis in Germany: data analysis of administrative prevalence and healthcare delivery in the statutory health systemBMC Health Serv Res20141438125209585
   PubMed Web of Science ®Google Scholar
• BonafedeMMJohnsonBHWatsonCHealth care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the USClinicoecon Outcomes Res20136112024379685
   PubMedGoogle Scholar
• ProsperiniLGianniCLeonardiLEscalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosisMult Scler2012181647121828195
   PubMed Web of Science ®Google Scholar
• Castillo-TrivinoTMowryEMGajofattoASwitching multiple sclerosis patients with breakthrough disease to second-line therapyPLoS One201162e1666421304907
   PubMed Web of Science ®Google Scholar
• KalincikTHorakovaDSpelmanTSwitch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosisAnn Neurol201577342543525546031
   PubMed Web of Science ®Google Scholar